Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Bristol-Myers Squibb Company

(

BMY

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Bristol-Myers Squibb Company rose 42 cents (1.3%) to $32.57 on average volume. Throughout the day, 11.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.8 million shares. The stock ranged in a price between $32.20-$32.74 after having opened the day at $32.35 as compared to the previous trading day's close of $32.15. Other companies within the Health Care sector that increased today were:

Ampio Pharmaceuticals

(

AMPE

), up 20.7%,

Medgenics

(

MDGN

), up 19.5%,

Cardium Therapeutics

(

CXM

), up 17.9%, and

Anthera Pharmaceuticals

(

ANTH

), up 14.7%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $53.34 billion and is part of the

drugs

industry. The company has a P/E ratio of 15.3, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 9.7% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, two analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Neuralstem

(

CUR

), down 16.3%,

Kips Bay Medical

(

KIPS

), down 12.7%,

Peregrine Pharmaceuticals

(

PPHM

), down 10.8%, and

Dynatronics Corporation

(

DYNT

), down 8.6%, were all laggards within the health care sector with

WellCare Health Plans

(

WCG

) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null